BUX — BioMark Diagnostics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$52.18m
- CA$52.66m
- CA$0.06m
Annual cashflow statement for BioMark Diagnostics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.45 | -1.84 | -1.43 | -1.93 | -1.48 |
| Depreciation | |||||
| Non-Cash Items | 0.028 | 0.404 | 0.138 | 0.428 | 0.101 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.043 | 0.138 | -0.086 | 0.005 | -0.095 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.2 | -0.914 | -0.983 | -1.09 | -1.09 |
| Capital Expenditures | -0.059 | -0.005 | -0.004 | -0.004 | -0.004 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | -0.392 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.059 | -0.005 | -0.004 | -0.004 | -0.396 |
| Financing Cash Flow Items | 0.694 | -0.09 | 0.262 | 0.224 | 0.055 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.768 | 0.609 | 1.07 | 3.42 | -0.378 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.495 | -0.311 | 0.085 | 2.33 | -1.86 |